The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNanoco Regulatory News (NANO)

Share Price Information for Nanoco (NANO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.60
Bid: 18.60
Ask: 18.98
Change: -0.07 (-0.37%)
Spread: 0.38 (2.043%)
Open: 20.00
High: 20.00
Low: 18.60
Prev. Close: 18.86
NANO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

22 Dec 2016 15:55

RNS Number : 6520S
Nanoco Group PLC
22 December 2016
 

For immediate release 22 December 2016

 

 

NANOCO GROUP PLC

("Nanoco" or the "Company" or "Group")

 

Director/PDMR Shareholding

 

The Company received notification today that, on 21 December 2016, Dr Michael Edelman, Nanoco's Chief Executive Officer, sold 380,000 ordinary shares and transferred 120,000 ordinary shares of £0.10 each in the Company ("Ordinary Shares") to meet charitable and other financial commitments before the end of the US tax year on 31 December 2016. The average sale price was 40.75 pence per share.

Following this transaction, Michael Edelman has a beneficial interest in 4,931,615 Ordinary Shares, representing approximately 2.07% per cent. of the total voting rights in the Company.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

 1

Details of the person discharging managerial responsibilities/person closely associated

 

a)

Name

Michael Edelman

 

2

Reason for the notification

 

a)

Position/status

 

CEO

b)

Initial notification/Amendment

 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name

 

Nanoco Group plc

b)

LEI

213800HOSJEZO1KOCV33

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument, type of instrument

 

Ordinary Shares of £0.10 each

 

Identification code

 

 

ISIN GB00B01JLR99

 

b)

Nature of the transaction

Sale and transfer of Ordinary Shares

 

c)

Price(s) and volume(s)

 

Sale:

 

Volume

Price, p

344,057

40.5p

31,166

43.0p

4,777

44.0p

 

 

Transfer:

Volume(s) 120,000 Ordinary Shares

Price(s) 44.5p transfer price (no cash received for charitable donation)

 

 

d)

Aggregated information

 

Sale;

Volume 380,000 Ordinary Shares

Average Price 40.75 pence

 

 

Transfer:

Volume 120,000 Ordinary Shares

Price 44.5p transfer price (no cash received for charitable donation)

 

e)

Date of transaction

21 December 2016

 

f)

Place of transaction

London Stock Exchange (XLON)

 

 

 

 

 

For further information, please contact:

 

Nanoco

Tel: +44 (0) 161 603 7900

Michael Edelman, Chief Executive Officer

 

David Blain, Chief Financial Officer

 

Caroline Watson, Investor Relations Manager

Tel: + 44 (0) 7799 897357

cwatson@nanocotechnologies.com

 

 

 

 

 

Buchanan

 

 

Tel: +44 (0) 20 7466 5000

Mark Court / Sophie Cowles / Stephanie Watson

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHAKBDQPBDDOBB
Date   Source Headline
25th Jul 20232:55 pmRNSPublication of Shareholder Presentation
25th Jul 202312:52 pmRNSNanoco Group Plc
24th Jul 20237:00 amRNSHigh Court Confirmation of Capital Reduction
20th Jul 20237:00 amRNSNotification of Investor Presentation
18th Jul 20237:00 amRNSPosting of Circular and Notice of General Meeting
7th Jul 202311:23 amRNSGeneral Meeting - Voting Results
28th Jun 20237:00 amRNSReceipt of General Meeting Requisition Notice
20th Jun 20237:00 amRNSPosting of Circular and Notice of General Meeting
9th Jun 20237:00 amRNSBlocklisting Six-Monthly Return
19th May 20231:00 pmRNSResponse to Shareholder Letter
21st Apr 20236:00 pmRNSHolding(s) in Company
30th Mar 202311:46 amRNSHolding(s) in Company
28th Mar 20237:00 amRNSInterim Results
27th Mar 20231:19 pmRNSResponse to Shareholder Letter
23rd Mar 20238:40 amRNSNotice of Results
9th Mar 20233:11 pmRNSHolding(s) in Company
9th Feb 20237:00 amRNSDirector/PDMR Shareholding
7th Feb 20237:00 amRNSHolding(s) in Company
3rd Feb 20237:15 amRNSTrading Update
3rd Feb 20237:15 amRNSLitigation Settlement Update
18th Jan 202311:35 amRNSHolding(s) in Company
16th Jan 202312:45 pmRNSHolding(s) in Company
11th Jan 20232:40 pmRNSHolding(s) in Company
10th Jan 20232:37 pmRNSHolding(s) in Company
9th Jan 20237:00 amRNSLitigation Settlement Update
6th Jan 20237:00 amRNSLitigation Outcome – Settlement Agreed
4th Jan 20233:31 pmRNSHolding(s) in Company
20th Dec 20223:51 pmRNSHolding(s) in Company
20th Dec 20222:59 pmRNSResult of AGM
20th Dec 20227:00 amRNSAGM Statement
13th Dec 20227:00 amRNSBlock listing Six-monthly Return
9th Dec 20227:00 amRNSLitigation Update - Firm Trial Date
14th Nov 202210:46 amRNS2022 Annual Report and Notice of AGM
7th Nov 20224:13 pmRNSHolding(s) in Company
27th Oct 20225:19 pmRNSDirector/PDMR Shareholding
26th Oct 20222:31 pmRNSLitigation Update – Funded Law Suit Filed in China
20th Oct 20227:00 amRNSPreliminary Results
14th Oct 202212:59 pmRNSPresentation via Investor Meet Company
14th Oct 202210:41 amRNSNotice of Results
28th Sep 20227:00 amRNSLitigation Update – Further Revised Trial Date
12th Sep 20228:25 amRNSTrading Update & Directorate Change
7th Sep 20223:47 pmRNSLitigation Update – Revised Trial Date
1st Sep 202210:22 amRNSDirector/PDMR Shareholding
31st Aug 20227:00 amRNSTwo Grant Funding Awards
30th Aug 20223:33 pmRNSHolding(s) in Company
30th Aug 20223:28 pmRNSDirector/PDMR Shareholding
25th Aug 20221:36 pmRNSDirector/PDMR Shareholding
23rd Aug 20222:22 pmRNSFunded Law Suit Filed in Germany
19th Aug 20228:21 amRNSLitigation Update – Pre-Trial Conference
18th Aug 20224:10 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.